Alfresa Partners with Kei Pharma on iPS Cell Therapy Supply Chain Development

In a significant move for regenerative medicine, Alfresa Corporation has officially entered into a basic partnership agreement with Kei Pharma regarding the supply chain for regenerative medical products derived from iPS cells. This partnership aims to enhance the availability of advanced therapies that could potentially offer new treatment options for previously untreatable diseases, thus responding to the rising expectations from the public for solutions in this vital area.

Background and Objectives of the Agreement

As of September 2025, Japan has approved 21 regenerative medical products, and further approvals for new products derived from iPS cells are anticipated in the near future. Recognizing the critical role of stable supply in healthcare, Alfresa Group specializes in the seamless provision of raw materials and delivery services to medical institutions, which is integral for the success of regenerative medicine. The initiative, called the